Reaching a dose and staying there for a year: a longitudinal note — does this still hold?

Asking directly, because I could not find a straight answer: Reaching a dose and staying there for a year: a longitudinal note — does this still hold?

I have read the maintained page on this and I still have a gap, so I am asking rather than guessing.

Context: retatrutide, 8 weeks in, currently at a dose I reached by the standard four-week steps. Everything below is my own record rather than anything a clinician told me.

The specific question is the one in the title. What I have already checked: the labelling summary on the relevant documentation page, the two most-linked topics in this subcategory, and my own notes from the last 13 weeks. What I could not find is whether the answer changes at higher doses or whether it is the same arithmetic throughout.

If the answer is "it depends", I would rather know what it depends on than be given a number.

Dose and effect are not linear across the studied range for every compound in this class. Assuming a doubled dose gives a doubled effect is the reasoning error behind most disappointment.

Not a strong opinion, just a consistent one.

Going back down a step is not a failure and the trials allowed it. Several protocols permitted a return to the previous dose for tolerability and then a second attempt at the step.

That is the shape of it. The detail is where I would expect to be corrected.

I had written a reply contradicting the opening post and deleted it. Here is what survived.

Writing down the date, the dose and the site each week takes fifteen seconds and is the single most useful record anyone here keeps. Memory reconstructs a titration history that never happened.

That is a fair summary of where the discussion has got to.

Escalating before steady state means you are judging a dose you have not yet fully experienced. That is the whole argument against compressing the schedule and it is a good one.

If anyone can point at the primary source I would be grateful.

Coming back to post #4, because the follow-up matters more than the original answer.

If symptoms reset at each step, that is the expected pattern rather than a sign that the previous adaptation was imaginary. Every dose increase is a new exposure.

Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The published trials used a calendar-based schedule. Tolerability-based escalation has no formal evidence base but is not uncommon in practice.

On balance I think that is right, and I would not bet much on it.

Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a weekly dosing schedule. Splitting it flattens the curve further but loses the convenience of once-weekly dosing. The trade-off is convenience versus a slightly flatter concentration curve.

I would treat that as a working assumption and revisit it.

Coming back to post #7, because the follow-up matters more than the original answer.

The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose strictly between them is off-label by definition. Some people compute it anyway. The reasoning is pharmacological — e.g., "I will split the difference between steps" — but it is reasoning from theory, not from evidence.

Reading it back, the second half matters more than the first.

Post #11 is right about the mechanism and I think understates the practical bit.

Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure, half-life, receptor selectivity, and in what has been studied clinically. One mg of semaglutide is not equivalent to one mg of something else in any meaningful sense.

This is the sort of thing the wiki should carry and currently does not.

Steady state means the plasma concentration is stable from dose to dose. That happens around 4 to 5 half-lives. Before that, the concentration is rising with each dose. Escalating before steady state means escalating on incomplete information about the dose you are on.

A partial answer, offered because a partial answer beats none.